History

Highlights and Milestones from Alvogen’s History 

Scroll through important milestones and highlights from our history, from 2009 until today.

1st
Year

2009 

This year Alvogen was founded on the strong foundation of Norwich Pharmaceutical services, with a 130-year history.

Business

Alvogen brand is introduced

People

Robert Wessman joins Alvogen as Chairman and CEO

Business

Alvogen launches Asia operations

Products

Alvogen acquires R&D capabilities from from Par Pharmaceutical

2nd
Year

2010 

International expansion started. Foundation laid in major fields of operation.

Business

Expansion in Eastern Europe - office opened in Bucharest Romania

People

Top executives appointed

Products

R&D center opens in Pinebrook, NJ

US pipeline

Alvogen teams up with Orchid in India

Business

Alvogen expands its operations in India

Business

Alvogen acquires Keri pharma

3rd
Year

2011 

International expansion continues. First products sold in the US market.

Products

First products launched in Thailand market

Alvogen & Natco

First-to-file on Tamiflu

Business

Alvogen opens new offices including Poland, Russia, Croatia, Macedonia, Albania and Kazakhstan

Pure Iceland

New OTC line launched in China

Business

US team hits record in sales

Norwich Clinical Services

NCS inaugurates a new clinical facility in India

Academic collaboration

Partnerships with MIT and Columbia University

4th
Year

2012 

Alvogen enters the APAC region through strategic acquisitions. Biosimilar partnership signed with Hospira.

India

CRO built in Bangalore

CEE region

Packaging Center built in Serbia

Biosimilar partnership

Biosimilar partnership signed with Hospira - first biosimilars sold in CEE

Products

First generic products sold in the APAC market

Awards

Alvogen US received DIANA merit award

APAC

Alvogen aquires majority in Kunwha

Awards

Norwich Pharmaceuticals received CMO leadership Award

5th
Year

2013 

Alvogen recognized for a dynamic growth in the US market and further steps taken in the development of the APAC platform.

Awards

Diana Award received

Award

Alvogen received CMO Leadership Awards for the second year running

Business

Aquisition of Labormed in Romania

Investment

Groundbreaking of a new biopharmaceuticals plant

Business

Alvogen acquires Naprelan® in the US

Business

Alvogen becomes the majority shareholder in Lotus Pharmaceuticals

Year

2014 

Biosimilar platform strengthened with new monoclonal antibodies launched in the CEE region. Alvogen aquires Korean Dream pharma.

Biosimilars

First to market with Inflectra in Europe with Hospira

Events & exhibitions

Alvogen scores high at CPhI 2014 for the third year in a row

Awards

Alvogen wins Diana "Oscar" for the third consecutive year

Awards

Alvogen receives double awards from the Generic bulletin

Business

Pamplona acquires stake in Alvogen

Business

Alvogen aquires Korean Dream pharma

Year

2015 

Strategic launches, prestigious consortium of new investor on board and Asian operations strengthened.

Business

Dream pharma and Kunwha pharmaceuticals become Alvogen Korea

Awards

Alvogen was honored as a Generic Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors

Products

Alvogen lauches the first generic Exelon® patch in the United States

Awards

Alvogen won EMEA company of the year awards from Generics Bulletin

Business

CVC capital partners leads investment consortium to acquire controlling stake in Alvogen

Year

2016 

Business expansion, Alvogen attracts intrest by Harvard business school and an opening of a state-of-the-art biosimilar facility.

Kick-off

Alvogen held its annual Kick-off in Phuket, Thailand. 115 company excecutives attended to discuss strategies and objectives

Business

Alvogen expands US business agreement signed to acquire County Line Pharmaceuticals

Academic

Alvogen in Harvard case study

Products

Alvogen announced the launch of the first generic equivalent of ZoladexTM in Central and Eastern Europe

Business

Alvotech opens state-of-the-art biosimilar facility in Iceland

Products

Alvogen launches first generic equivalent of Copaxone(TM) in Europe

Products

Alvogen launches the first generic equivalent to Tamiflu® capsules in the United States

Year

2017 

Successful events and strategic product launches.

Kick-off

Global Kick-off in Malta

Products

Alvogen first to market with generic equivalent to Tamiflu® powder for oral suspension

Products

First approval for glatiramer acetate in Europe

Events & exhibitions

CPhI in Frankfurt was a great success for Alvogen

Products

Alvogen subsidiary confirms ANDA filing and patient challenge for generic Revlimid®

Products

Alvogen adds Qsymia to its anti-obesity portfolio in Korea

Business

Alvogen acquires Omega Bittner, a Russia-based pharmaceutical firm, and significantly strengthens the regions portfolio

Highlights and Milestones from Alvogen’s History
2009
2010
2011
2012
2013
2014
2015
2016
2017
We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.